ISA 2022 | Imaging modalities to diagnose and monitor AL & ATTR amyloidosis
Marianna Fontana, MD, PhD, University College London, London, UK, comments on imaging modalities used for the diagnosis and monitoring of ATTR and cardiac AL amyloidosis. Prof. Fontana explains that whilst echocardiography, bone scintigraphy, and cardiac MRI can be used at diagnosis, only bone scintigraphy and cardiac MRI can confirm the diagnosis of ATTR amyloidosis. Prof. Fontana further highlights the emerging role of cardiac MRI with T1 mapping at diagnosis and for monitoring in patients with cardiac AL amyloidosis. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy for: Alnylam, Ionis, Intellia, Novonordisk, Janssen, Caelum, Pfizer, Bridgbio, Eidos
